RT Journal Article
SR Electronic
T1 The SARS-CoV-2 Alpha variant causes increased clinical severity of disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.17.21260128
DO 10.1101/2021.08.17.21260128
A1 David J. Pascall
A1 Guy Mollett
A1 Rachel Blacow
A1 Naomi Bulteel
A1 Robyn Campbell
A1 Alasdair Campbell
A1 Sarah Clifford
A1 Chris Davis
A1 Ana da Silva Filipe
A1 Ludmila Fjodorova
A1 Ruth Forrest
A1 Emily Goldstein
A1 Rory Gunson
A1 John Haughney
A1 Matthew T.G. Holden
A1 Patrick Honour
A1 Joseph Hughes
A1 Edward James
A1 Tim Lewis
A1 Samantha Lycett
A1 Martin McHugh
A1 Yusuke Onishi
A1 Ben Parcell
A1 David L Robertson
A1 Noha El Sakka
A1 Sharif Shabaan
A1 James G. Shepherd
A1 Katherine Smollett
A1 Kate Templeton
A1 Elen Vink
A1 Elizabeth Wastnedge
A1 Thomas Williams
A1 The COVID-19 Genomics UK (COG-UK) consortium
A1 Emma C. Thomson
YR 2021
UL http://medrxiv.org/content/early/2021/08/24/2021.08.17.21260128.abstract
AB Background The B.1.1.7 (Alpha) SARS-CoV-2 variant of concern was associated with increased transmission relative to other variants present at the time of its emergence and several studies have shown an association between the B.1.1.7 lineage infection and increased 28-day mortality. However, to date none have addressed the impact of infection on severity of illness or the need for oxygen or ventilation.Methods In this prospective clinical cohort sub-study of the COG-UK consortium, 1475 samples from hospitalised and community cases collected between the 1st November 2020 and 30th January 2021 were collected. These samples were sequenced in local laboratories and analysed for the presence of B.1.1.7-defining mutations. We prospectively matched sequence data to clinical outcomes as the lineage became dominant in Scotland and modelled the association between B.1.1.7 infection and severe disease using a 4-point scale of maximum severity by 28 days: 1. no support, 2. oxygen, 3. ventilation and 4. death. Additionally, we calculated an estimate of the growth rate of B.1.1.7-associated infections following introduction into Scotland using phylogenetic data.Results B.1.1.7 was responsible for a third wave of SARS-CoV-2 in Scotland, and rapidly replaced the previously dominant second wave lineage B.1.177) due to a significantly higher transmission rate (∼5 fold). Of 1475 patients, 364 were infected with B.1.1.7, 1030 with B.1.177 and 81 with other lineages. Our cumulative generalised linear mixed model analyses found evidence (cumulative odds ratio: 1.40, 95% CI: 1.02, 1.93) of a positive association between increased clinical severity and lineage (B.1.1.7 versus non-B.1.1.7). Viral load was higher in B.1.1.7 samples than in non-B.1.1.7 samples as measured by cycle threshold (Ct) value (mean Ct change: -2.46, 95% CI: -4.22, -0.70).Conclusions The B.1.1.7 lineage was associated with more severe clinical disease in Scottish patients than co-circulating lineages.Funding COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Funding was also provided by UKRI through the JUNIPER consortium (grant number MR/V038613/1). Sequencing and bioinformatics support was funded by the Medical Research Council (MRC) core award (MC UU 1201412).Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Funding was also provided by UKRI through the JUNIPER consortium (grant number MR/V038613/1). Sequencing and bioinformatics support was funded by the Medical Research Council (MRC) core award (MC UU 1201412).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual nucleic acid extracts derived from the nose-throat swabs of SARS-CoV-2 positive individuals whose diagnostic samples were submitted to the West of Scotland Specialist Virology Centre and Edinburgh Royal Infirmary Virus laboratory and were sequenced as part of the COG-UK consortium following ethical approvals from the West of Scotland Biorepository (16/WS/0207NHS; approved on the 27th March 2020) and the Lothian Biorepository (10/S1402/33; approved 1st May 2015). PHE Research Ethics and Governance Group (REGG) approval was granted on the 8th April 2020 (NR0195). Caldicott approval was obtained at all participating Scottish sites for use of clinical data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the analysis of patient identifiable data, please contact the authors for data requests.